NinaMED

Melbourne, AustraliaFounded 2026meetninamed.com

NinaMED is developing NiNA, a treatment intended for people with overactive bladder (OAB). The product is designed as an alternative to medication and invasive or clinic-based therapies, with the aim of helping patients manage symptoms and improve quality of life.

Visit meetninamed.com ↗

Founded: 2026

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

NinaMED’s May 2026 launch marked its emergence as a company focused on commercializing the NiNA System for overactive bladder. On May 13, it closed a Seed round of AUD 13.75 million, equivalent to approximately USD 9.95 million in the company’s funding figures, with SPRIM Global Investments identified as lead investor. The financing was presented as supporting advancement of the licensed NiNA System. On May 14, NinaMED announced an exclusive global licensing agreement with EBT Medical, giving NinaMED rights to commercialize the system worldwide. The same announcement introduced three board appointments: Professor Ian Meredith as Chair, and Kelly Constable and Steffen Hovard as Non-Executive Directors. These appointments add board-level oversight as the company moves toward commercialization. The available public record does not specify regulatory clearances, launch markets, sales, or clinical outcomes, so the commercial and clinical progress of the product cannot yet be assessed from these milestones alone. There is also a discrepancy between the USD-converted funding figure and some announcement headlines that describe the financing as US$13.75 million; the funding total here uses the converted figure.

Market position

NinaMED operates in healthcare and medical devices, with a specific focus on overactive bladder (OAB). Its stated product, NiNA, is intended as a non-invasive treatment option and is positioned as an alternative or complement to medication and more invasive or clinic-based approaches. This gives the company a defined condition-specific focus rather than a broad medical-device portfolio. NinaMED’s May 2026 exclusive global licensing agreement with EBT Medical provides the commercialization rights to the NiNA System, while the May 13 Seed financing of AUD 13.75 million (approximately USD 9.95 million using the funding figures available) supplies initial capital for its development and commercialization plans. No comparable companies or named competitors are identified in the available company information, so a reliable company-by-company competitive comparison is not possible. The record also does not establish the product’s regulatory status, clinical evidence, pricing, reimbursement position, or market availability. Those factors will be important to judging how NiNA compares with medication, existing neuromodulation approaches, and other OAB therapies. Its current distinction is therefore its focused OAB indication and non-invasive treatment intent, rather than demonstrated market share or proven commercial differentiation.

Growth & opportunities

NinaMED’s profile suggests an early-stage company moving from formation toward product commercialization. It was founded in 2026 and announced a Seed round on May 13, 2026, totaling AUD 13.75 million; the structured funding figure converts this to approximately USD 9.95 million. SPRIM Global Investments is named as the round’s lead investor. A day later, NinaMED announced an exclusive global licensing agreement with EBT Medical for the NiNA System, giving it rights to commercialize the non-invasive OAB therapy worldwide. This licensing agreement and financing are the clearest inflection points in the available timeline: they establish access to the product and provide reported capital for the next phase. Board appointments announced on May 14—Professor Ian Meredith as Chair, with Kelly Constable and Steffen Hovard as Non-Executive Directors—also indicate a build-out of governance around commercialization. As a result, NinaMED’s trajectory can be characterized as newly funded and commercialization-oriented, but the pace and success of execution remain unverified.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes NinaMED distinct

reccy insights

What makes NinaMED distinct

01Focuses specifically on overactive bladder, a condition that can be underdiagnosed or untreated.
02Positions NiNA as an option earlier in the treatment journey, alongside or as an alternative to medication.
03Aims to avoid invasive surgery and the burden of pharmaceutical side effects.
04Frames patient confidence, freedom, and dignity as intended benefits of treatment.

Technology & products

NiNA
A non-invasive therapy intended to help treat overactive bladder.

NiNA, a product intended for the treatment of overactive bladder.
The NiNA System is described as a non-invasive therapy.

Recent updates2

Launches, partnerships and team changes from press coverage

May 14, 2026Partnership
NinaMED entered into a licensing agreement with EBT Medical for exclusive global rights to the NiNA System, enabling NinaMED to commercialize the non-invasive overactive bladder therapy worldwide.
startupresearcher.com
May 14, 2026Team change
NinaMED appointed Professor Ian Meredith as Chair of its board, with Kelly Constable and Steffen Hovard joining as Non-Executive Directors to guide the company’s commercialization strategy.
startupresearcher.com

About NinaMED

Products: NiNA
Leadership: Professor Ian Meredith, ChairKelly Constable, Non-Executive DirectorSteffen Hovard, Non-Executive Director
Focus areas: Healthcare, medical devices, overactive bladder, urinary health, Non-Invasive therapy
Headquarters: Melbourne, Australia
Founded: 2026